15.03.370 Testing of Lots

(a) Sampling and testing of each lot of final medical marijuana product shall be conducted with a statistically significant number of samples and with acceptable methodologies, approved by the Authority, such that there is assurance that all lots of each medical marijuana product are adequately assessed for contaminants and the cannabinoid profile is consistent throughout.

(b) Testing of the cannabinoid profile shall include, at a minimum, those analytes in Subchapter 8.

(c) Testing for contaminants in the final medical marijuana product shall include but shall not be limited to those analytes listed below. The Authority shall make available a list of required analytes and their acceptable limits as determined by the Authority.

Analyte:

coli

Pseudomonas (for products to be vaporized)

Salmonella species

Enterococcus species

Bile tolerant gram negative bacteria, specifically including Klebsiella species

Clostridium botulinum

Aspergillus species

Mucor species

Penicillium species

Thermophilic Actinomycetes species

Aflatoxins B1, B2, G1, G2

Ochratoxin A

Antimony

Arsenic

Cadmium

Chromium

Copper

Lead

Nickel

Zinc

Mercury

Any pesticide used during production of the medical marijuana product

Any growth regulator used during production of the medical marijuana product

Any other analyte as required by the Authority